Patients with antiphospholipid syndrome (APS) have an increased risk for the development of thrombotic complications. Recent studies indicate that osteoprotegerin (OPG) acts as an important molecule in the development of vascular diseases. The aim of the present study was to examine the association between serum OPG levels and APS manifestations in patients with SLE. Seventy-nine patients with SLE and ninety-two healthy controls, matched for age and sex, were included in this study. Serum levels of OPG, monocyte chemoattractant protein(MCP)-1 and soluble E-selectin were determined by ELISA. At the time of serum sampling, various clinical and laboratory parameters were assessed. We found that serum levels of OPG were significantly higher in patients with SLE than in healthy controls (1236 ± 82 vs 967 ± 37 pg/mL, P = 0.003). Particularly, serum OPG levels were significantly higher in SLE patients with APS than those without (1615 ± 191 vs 1171 ± 91 pg/mL, P = 0.006). Serum OPG levels correlated with titres of IgG anti-cardiolipin antibody (P = 0.026) and anti-β2-glycoprotein I antibody (P < 0.001). Moreover, serum OPG also correlated with serum levels of sE-selectin (P = 0.002), which is an endothelial cell activation marker, and MCP-1 (P = 0.003), a well known chemokine implicated in thrombogenesis. Collectively, serum OPG levels were increased in SLE patients with APS and correlated with titres of antiphospholipid antibodies, suggesting that OPG might be linked to the development of APS.
1 Simonet WS Lacey DL Dunstan CR . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell1997; 89: 309–319.
2.
2 Yasuda H Shima N Nakagawa N . Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis -inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A1998; 9: 3597–3602.
3.
3 Hofbauer LC Shui C Riggs BL . Effects of immunosuppressants on receptor activator of NF- kappa B ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun2001; 280: 334–339.
4.
4 Dhore CR Cleutjens JP Lutgens E . Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol2001; 21: 1998–2003.
5.
5 Malyankar UM Scatena M Suchland KL Yun TJ Clark EA Giachelli CM . Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. J Biol Chem2000; 275: 20959–20962.
6.
6 Bucay N Sarosi I Dunstan CR . Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev1998; 12: 1260–1268.
7.
7 Jono S Ikari Y Shioi A . Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation2002; 106: 1192–1194.
8.
8 Schoppet M Sattler AM Schaefer JR Herzum M Maisch B Hofbauer LC . Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab2003; 88: 1024–1028.
9.
9 Browner WS Lui LY Cummings SR . Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab2001; 86: 631–637.
10.
10 Skoumal M Kolarz G Woloszczuk W Hawa G Klingler A . Serum osteoprotegerin but not receptor activator of NF-kappaB ligand correlates with larsen score in rheumatoid arthritis. Ann Rheum Dis2004; 63: 216–217.
11.
11 Skoumal M Kolarz G Haberhauer G Woloszczuk W Hawa G Klingler A . Osteoprotegerin and the receptor activator of NF-kappa B ligand in the serum and synovial fluid. A comparison of patients with longstanding rheumatoid arthritis and osteoarthritis. Rheumatol Int2005; 26: 63–69.
12.
12 Rhee EJ Lee WY Kim SY . Relationship of serum osteoprotegerin levels with coronary artery disease severity, left ventricular hypertrophy and C-reactive protein. Clin Sci (Lond)2005; 108: 237–243.
13.
13 Bernstein CN Sargent M Leslie WD . Serum osteoprotegerin is increased in crohn's disease: a population-based case control study. Inflamm Bowel Dis2005; 11: 325–330.
14.
14 Simonini G Masi L Giani T . Osteoprotegerin serum levels in Kawasaki disease: an additional potential marker in predicting children with coronary artery involvement. J Rheumatol2005; 32: 2233–2238.
15.
15 Levine SR Salowich-Palm L Sawaya KL . IgG anticardiolipin antibody titer >40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke1997; 28: 1660–1665.
16.
16 Maaravi Y Raz E Gilon D Rubinow A . Cerebrovascular accident and myocardial infarction associated with anticardiolipin antibodies in a young woman with systemic lupus erythematosus. Ann Rheum Dis1989; 48: 853–855.
17.
17 Zuckerman E Toubi E Shiran A . Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am J Med1996; 101: 381–386.
18.
18 Farsi A Domeneghetti MP Fedi S . High prevalence of anti-beta2 glycoprotein I antibodies in patients with ischemic heart disease. Autoimmunity1999; 30: 93–98.
19.
19 Fiallo P Tomasina C Clapasson A Cardo PP . Antibodies to beta(2)-glycoprotein I in ischemic stroke. Cerebrovasc Dis2000; 10: 293–297.
20.
20 Tanne D Triplett DA Levine SR . Antiphospholipid-protein antibodies and ischemic stroke: not just cardiolipin any more. Stroke1998; 29: 1755–1758.
21.
21 Hochberg MC . Updating the American college of rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
22.
22 Wilson WA Gharavi AE Koike T . International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum1999; 42: 1309–1311.
23.
23 Bombardier C Gladman DD Urowitz MB Caron D Chang CH . Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum1992; 35: 630–640.
24.
24 Nellemann B Gormsen LC Dollerup J . Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care2007; 30: 3122–3124.
25.
25 Ben-Tal Cohen E Hohensinner PJ Kaun C Maurer G Huber K Wojta J . Statins decrease TNF-alpha-induced osteoprotegerin production by endothelial cells and smooth muscle cells in vitro. Biochem Pharmacol2007; 73: 77–83.
26.
26 Viereck V Gründker C Blaschke S . Atorvastatin stimulates the production of osteoprotegerin by human osteoblasts. J Cell Biochem2005; 96: 1244–1253.
27.
27 Kaji H Kanatani M Sugimoto T Chihara K . Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures. Horm Metab Res2005; 37: 589–592.
28.
28 Leeuwenberg JF Smeets EF Neefjes JJ . E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology1992; 77: 543–549.
29.
29 Szulc P Hofbauer LC Heufelder AE Roth S Delmas PD . Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab2001; 86: 3162–3165.
30.
30 Khosla S Arrighi HM Melton LJ . Correlates of osteoprotegerin levels in women and men. Osteoporos Int2002; 13: 394–399.
31.
31 Ziolkowska M Kurowska M Radzikowska A . High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum2002; 46: 1744–1753.
32.
32 Collin-Osdoby P Rothe L Anderson F Nelson M Maloney W Osdoby P . Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. J Biol Chem2001; 276: 20659–20672.
33.
33 Zhang J Fu M Myles D . PDGF induces osteoprotegerin expression in vascular smooth muscle cells by multiple signal pathways. FEBS Lett2002; 521: 180–184.
34.
34 Pantsulaia I Trofimov S Kobyliansky E Livshits G . Contribution of the familial and genetic factors on monocyte chemoattractant protein-1 variation in healthy human pedigrees. Cytokine2005; 32: 117–123.
35.
35 Schoppet M Preissner KT Hofbauer LC . RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol2002; 22: 549–553.
36.
36 Cho CS Cho ML Chen PP . Antiphospholipid antibodies induce monocyte chemoattractant protein-1 in endothelial cells. J Immunol2002; 168: 4209–4215.
37.
37 Mosheimer BA Kaneider NC Feistritzer C . Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. J Clin Endocrinol Metab2005; 90: 2964–2971.
38.
38 Mangan SH Campenhout AV Rush C Golledge J . Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-alpha associated with induction of angiopoietin-2. Cardiovasc Res2007; 76: 494–505.
39.
39 Zannettino AC Holding CA Diamond P . Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol2005; 204: 714–723.
